Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 12, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial results, operational updates, or strategic commentary for the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not report consolidated financial performance.
Material Changes and Transaction Details
The filing discloses nine separate transactions executed on April 11, 2018, on the London Stock Exchange (XLON). All transactions involved the acquisition of Ordinary Shares (ISIN: GB0009252882) under the Company's Share Reward Plan. The details are as follows:
- Transaction Price: All shares were acquired at a price of £14.3479 per share.
- Participants and Volumes:
- Ms E Walmsley (CEO): 16 shares (8 partnership, 8 matching).
- Mr R G Connor (President, Global Manufacturing & Supply): 16 shares (8 partnership, 8 matching).
- Mr S Dingemans (CFO): 16 shares (8 partnership, 8 matching).
- Mr N Hirons (SVP, Global Ethics & Compliance): 16 shares (8 partnership, 8 matching).
- Mr L Miels (President, Global Pharmaceuticals): 16 shares (8 partnership, 8 matching).
- Mr D S Redfern (Chief Strategy Officer): 16 shares (8 partnership, 8 matching).
- Ms C Thomas (SVP, Human Resources): 16 shares (8 partnership, 8 matching).
- Mr P C Thomson (President, Global Affairs): 18 shares (9 partnership, 9 matching).
- Mrs V A Whyte (Company Secretary): 16 shares (8 partnership, 8 matching).
- Total Volume: 146 Ordinary Shares were acquired in total across all listed transactions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory reporting of the aforementioned share acquisitions.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs under the Share Reward Plan for the quarter.
- Confirm the transaction date (April 11, 2018) and execution venue (London Stock Exchange).
- Review the specific roles of the individuals involved to assess alignment with company strategy.
- Note that this filing contains no financial performance data; refer to Form 20-F or quarterly earnings releases for financial metrics.